Is it time to target no evident disease activity (NEDA) in multiple sclerosis? (Q26801550)

Europe PubMed Central

title

Is it time to target no evident disease activity (NEDA) in multiple sclerosis? (English)

0 references

0 references

1

Gavin Giovannoni

0 references

author name string

Benjamin Turner

2

0 references

Sharmilee Gnanapavan

3

0 references

Curtis Offiah

4

0 references

Klaus Schmierer

5

0 references

Monica Marta

Multiple Sclerosis and Related Disorders

6

0 references

language of work or name

English

0 references

publication date

July 2015

0 references

published in

1 reference

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic

PubMed

volume

4

0 references

page(s)

329-33

0 references

issue

4

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Editors' welcome and a working definition for a multiple sclerosis cure

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Evidence for a two-stage disability progression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Measures in the first year of therapy predict the response to interferon β in MS

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 'Spinal Tap'

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Scoring treatment response in patients with relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Assessing treatment response to interferon-β: is there a role for MRI?

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.04.006

7 January 2021